BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioSilta Introduces EnPresso B Growth Systems for Bacterial Cultures


6/24/2013 10:14:29 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Oulu, Finland, 24th June 2013: BioSilta Oy, a developer of advanced microbial growth systems, today announced the commercial launch of the first products in its proprietary EnPresso® B range of reagent-based growth systems for bacterial cultures. Extensive results from independent labs around the world (available at www.biosilta.com) have confirmed that these new products typically increase protein yields by five to 100-fold and improve protein functionality when compared to results using conventional growth media.

The EnPresso B range has been developed in response to findings from market research involving over 1,200 scientists routinely growing bacterial cultures for the expression of recombinant proteins at laboratory scale. The majority of respondees highlighted insufficient yield, followed by quality problems such as poor protein solubility or low activity, as their main challenges.

The products are EnPresso B, EnPresso B Animal-free (supplied with documentation to certify that the product is free from animal-derived components), and EnPresso B Defined Nitrogen-free, used to significantly increase the yield of 15N-labeled proteins for NMR analysis.

For ease of use the products are supplied as pre-sterilized tablets, which are simply added to sterile, filtered water. Optimized protocols enable researchers to go from pre-culture to harvest within two days, using standard lab equipment such as shake flasks or 24 deep well plates.

The EnPresso B range incorporates the Company’s patented EnBase® technology that offers a novel approach to control the feeding, and thereby growth rate, of microbial cultures. A glucose-releasing agent breaks down long chains of polysaccharides, releasing glucose units to feed the microbes. As well as glucose, EnPresso tablets provide other key elements to support growth and control pH. Cells grow steadily to reach higher densities before induction of protein expression and continue in linear growth for many hours after induction. Proteins are expressed under optimal metabolic conditions thereby reducing the risk of incorrect folding and increasing the percentage of soluble protein. In contrast, microbes cultivated in conventional media grow in an uncontrolled manner, consuming nutrients, changing pH and depleting oxygen. Growth stops within hours, limiting protein yields and ‘too fast’ metabolism produces poor quality proteins.

Bob Penney, CEO, BioSilta Oy, said: “In our market research over 70% of scientists confirmed that their main challenge when producing recombinant proteins in bacterial systems was insufficient yield, followed by problems with poor solubility and functionality. We firmly believe that EnPresso B growth systems very significantly address these issues and will revolutionize the role of bacterial cell culture in protein expression. Scientists will spend less time optimizing expression systems and more time focused on their true research objectives.”

For a high-resolution image please contact lorna.cuddon@zymecommunications.com

For more information please contact:

Lorna Cuddon, Zyme Communications

lorna.cuddon@zymecommunications.com

+44 (0)7811996942

About BioSilta http://biosilta.com/

BioSilta is a privately-held company that utilizes its unique, proprietary EnBase® technology platform to develop innovative, reagent-based EnPresso® growth systems. When compared to conventional growth media, these growth systems significantly increase the yield of high quality biomolecules from microbial cultures.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

BioSilta
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES